Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2007
02/08/2007WO2007016525A2 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
02/08/2007WO2007016496A2 Dipiperazinyl ketones and related analogues
02/08/2007WO2007016455A2 Compositions and methods using aminoglycosides to bind dna and rna
02/08/2007WO2007016450A2 Methods for treating or preventing reactivation of a latent herpesvirus infection
02/08/2007WO2007016410A2 High viscosity antibacterials
02/08/2007WO2007016392A2 Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
02/08/2007WO2007016390A1 Matrix metalloproteinase inhibitors for treating fatty liver disease
02/08/2007WO2007016388A2 Liquid formulations for controlled delivery of benzisoxazole derivatives
02/08/2007WO2007016385A2 Use of substituted 5-amino-1h-pyrrole-2-carbonitrile derivatives as progesterone receptor modulators
02/08/2007WO2007016361A2 Novel pharmaceutical compounds
02/08/2007WO2007016358A1 N-(pyridin-4-yl)-2-phenylbutanamides as androgen receptor modulators
02/08/2007WO2007016357A1 Amyloid beta receptor and uses thereof
02/08/2007WO2007016356A1 Methods of preparing hetercyclic boronic acids and derivatives thereof
02/08/2007WO2007016354A1 Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
02/08/2007WO2007016353A2 Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
02/08/2007WO2007016292A2 Heterocyclic amides as biofilm modulators
02/08/2007WO2007016287A2 Pdt treatment method for cellulites and cosmetic use
02/08/2007WO2007016256A2 Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
02/08/2007WO2007016254A2 Antineoplastic activities of ellipticine and its derivatives
02/08/2007WO2007016228A2 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
02/08/2007WO2007016212A1 Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof
02/08/2007WO2007016211A1 Cyanopyrrole-phenyl amide progesterone receptor modulators and uses thereof
02/08/2007WO2007016209A2 Pure 1,2-benzisoxazole-3-methane-sulfonic acid sodium salt and purification process
02/08/2007WO2007016208A2 1,2-benzisoxazole-3-methane-sulfonic acid ammonium salt
02/08/2007WO2007016203A1 Method of improving wakefulness
02/08/2007WO2007016202A1 Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
02/08/2007WO2007016201A2 FORMULATION OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
02/08/2007WO2007016190A2 Antiparkinsonian action of phenylisopropylamines
02/08/2007WO2007016156A2 Topical anti-pruritic compositions and methods of action of same
02/08/2007WO2007016155A2 Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
02/08/2007WO2007016147A2 Topical skin protectant and anti-pruritic compositions
02/08/2007WO2007016139A2 Crystalline non-solvated methanesulfonic acid salt of 1-(4-(2-piperidinylethoxy)phenoxy)-2-(3-hydroxyphenyl)-6-hydroxynaphthalene
02/08/2007WO2007016136A2 Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
02/08/2007WO2007016134A1 BICYCLIC 6-ALKYLIDENE-PENEM B-LACTAMASE INHIBITORS AND β-LACTAM ANTIBIOTIC COMBINATION: A BROAD SPECTRUM ANTIBIOTIC
02/08/2007WO2007016128A2 Magnesium salt proton pump inhibitor dosage forms
02/08/2007WO2007016108A1 Compositions for affecting weight loss
02/08/2007WO2007016095A2 Cyclooxygenase-2 selective inhibitor compounds comprising nitric oxide enhancing groups, compositions and methods of use
02/08/2007WO2007016087A2 Heterocyclic benzodiazepine cgrp receptor antagonists
02/08/2007WO2007016028A2 Synthesis and crystalline forms of npy5 antagonist
02/08/2007WO2007015937A1 Phosphorytated glucomannan polysaccharides containing 1-6 and 1-2 linkages increase weight gain in swine
02/08/2007WO2007015932A1 Phosphorylated glucomannane polysaccharides containing 1-6 and 1-2 linkages increase weight gain in poultry
02/08/2007WO2007015929A2 Epothilone analogues
02/08/2007WO2007015885A2 Method of using a biosealant device
02/08/2007WO2007015871A1 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
02/08/2007WO2007015870A2 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
02/08/2007WO2007015812A2 Hiv reverse transcriptase inhibitors
02/08/2007WO2007015807A1 Phenyl compounds
02/08/2007WO2007015805A1 1-amino linked compounds
02/08/2007WO2007015775A2 Potassium channel inhibitors
02/08/2007WO2007015767A1 Pyridine derivatives as dipeptedyl peptidase inhibitors
02/08/2007WO2007015757A2 Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators
02/08/2007WO2007015744A1 Disubstituted thienyl compounds and their use as pharmaceuticals
02/08/2007WO2007015724A1 Tromethamine salt of valproic acid
02/08/2007WO2007015668A1 New salt iii
02/08/2007WO2007015667A1 New salt ii
02/08/2007WO2007015666A1 New salt i
02/08/2007WO2007015664A1 Novel piperidine derivatives as chemokine receptor modulators useful for the treatment of respiratory diseases.
02/08/2007WO2007015588A1 Piperidine derivative as tachykinin receptor antagonist
02/08/2007WO2007015587A1 Apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer, screening method for the promoter, inhibitor or agent
02/08/2007WO2007015585A1 Agent for reduction of oxidized albumin level
02/08/2007WO2007015578A1 Method for assay on the effect of vascularization inhibitor
02/08/2007WO2007015569A1 Method for prediction of the efficacy of vascularization inhibitor
02/08/2007WO2007015567A1 Cyclic amine compound
02/08/2007WO2007015528A1 Agent for treating and/or preventing sleep disorder
02/08/2007WO2007015510A1 Method for prevention of degradation of thermally unstable substance
02/08/2007WO2007015453A1 Lotion preparation containing pyridonecarboxylic acid derivative
02/08/2007WO2007015280A1 Benzodiazepine derivatives and uses thereof in medical field
02/08/2007WO2007015270A2 Novel controlled release compositions of selective serotonin reuptake inhibitors
02/08/2007WO2007015175A2 Use of pp-1 inhibitors to prevent missplicing events
02/08/2007WO2007015170A2 Synapse-specific proteins in glomeruli
02/08/2007WO2007015162A1 Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
02/08/2007WO2007015161A1 Novel substituted azetidinones
02/08/2007WO2007015122A1 Therapy for alzheimer’s disease
02/08/2007WO2007015112A1 Antitumoral compounds
02/08/2007WO2007015102A1 The use of charcoal for treating inflammatory conditions
02/08/2007WO2007015064A1 Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
02/08/2007WO2007015027A1 Cosmetic and/or dermatological composition for prevention and/or treatment of sensitive or dry skin
02/08/2007WO2007015017A2 Novel polyquinoline derivatives and the therapeutic use thereof
02/08/2007WO2007015004A2 Novel crystalline v form of agomelatine, method of the preparation thereof and pharmaceutical compositions containing said form
02/08/2007WO2007015003A2 Novel crystalline iii form of agomelatine, method of the preparation thereof and pharmaceutical compositions containing said form
02/08/2007WO2007015002A2 Novel crystalline iv form of agomelatine, method of the preparation thereof and pharmaceutical compositions containing said form
02/08/2007WO2007014943A2 Therapy for neurological diseases
02/08/2007WO2007014941A2 Quinoline derivatives as antibacterial agents
02/08/2007WO2007014929A1 Use of flibanserin in the treatment of obesity
02/08/2007WO2007014928A1 Pharmaceutical composition comprising granular pantoprazole
02/08/2007WO2007014926A1 Macrocyclic inhibitors of hepatitis c virus
02/08/2007WO2007014925A1 Macrocylic inhibitors of hepatitis c virus
02/08/2007WO2007014924A1 Macrocyclic inhibitors of hepatitis c virus
02/08/2007WO2007014923A1 Macrocyclic inhibitors of hepatitis c virus
02/08/2007WO2007014922A1 Macrocyclic inhibitors of hepatitis c virus
02/08/2007WO2007014921A1 Macrocyclic inhibitors of hepatitis c virus
02/08/2007WO2007014920A1 Macrocyclic inhibitors of hepatitis c virus
02/08/2007WO2007014918A1 Macrocyclic inhibitors of hepatitis c virus
02/08/2007WO2007014895A2 Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives
02/08/2007WO2007014886A1 Hydrochlorides and hydrates of 1-[(3-cyanopyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-aminopiperidin-1-yl)xanthine, their preparation and their use as medicaments
02/08/2007WO2007014885A1 Antibacterial quinoline derivatives
02/08/2007WO2007014872A1 Combination of itriglumide and proton pump inhibitors in the treatment of gastrointestinal and related disorders
02/08/2007WO2007014843A1 2-hydroxy-propionic acid derivatives and 3-hydroxy-benzofuran-2-one derivatives with affinity for the gaba-b-receptor
02/08/2007WO2007014838A1 Dihydropteridinones in the treatment of respiratory diseases
02/08/2007WO2007014756A1 Liquid formulation based on a guanidinoacetic acid component